Literature DB >> 32401372

Safety and feasibility of hematopoietic progenitor stem cell collection by mobilization with plerixafor followed by apheresis vs bone marrow harvest in patients with sickle cell disease in the multi-center HGB-206 trial.

John F Tisdale1, Francis J Pierciey2, Melissa Bonner2, Alexis A Thompson3,4, Lakshmanan Krishnamurti5, Markus Y Mapara6, Janet L Kwiatkowski7,8, Ilya Shestopalov2, Jean-Antoine Ribeil2, Wenmei Huang2, Mohammed Asmal2, Julie Kanter9, Mark C Walters10.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32401372     DOI： 10.1002/ajh.25867

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  2 in total

1.  Process and procedural adjustments to improve CD34+ collection efficiency of hematopoietic progenitor cell collections in sickle cell disease.

Authors:  Scott T Avecilla; Farid Boulad; Karina Yazdanbakhsh; Michel Sadelain; Patricia A Shi
Journal:  Transfusion       Date:  2021-06-23       Impact factor: 3.337

2.  Evidence for continued dose escalation of plerixafor for hematopoietic progenitor cell collections in sickle cell disease.

Authors:  Farid Boulad; Jiahao Zhang; Karina Yazdanbakhsh; Michel Sadelain; Patricia A Shi
Journal:  Blood Cells Mol Dis       Date:  2021-06-15       Impact factor: 2.372
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.